Fat loss drug top pharma seller, Augmentin no 2
The Weight of Change: How Semaglutide Shook Up India’s Pharma Rankings India’s pharmaceutical landscape is constantly shifting, driven by evolving health needs and the introduction ...
Cipla’s leadership change: Achin Gupta to succeed Umang Vohra
A New Chapter for Cipla: Achin Gupta Takes the Helm Change is the only constant, especially in the fast-paced world of pharmaceuticals. And at Cipla, ...
Pharma expansion: Natco to acquire major stake in South Africa’s Adcock Ingram, firm to go private
Indian firm Natco Pharma is set to acquire substantial stakes in South African pharmaceutical company Adcock Ingram. This deal, valued at R4.2 billion, will transition ...
Trump’s 100% tariffs on branded drugs: Indian generics spared but poses risks for pharma sector – Explained
US President Trump announced a 100% tariff on imported branded and patented pharmaceuticals starting October 2025, aiming to boost domestic manufacturing. Indian generic drug makers ...
Trump’s 100% pharma tariffs: How bad will India’s pharmaceutical exports be hit? L’ow-cost generic model may offer cushion’
Donald Trump announced 100% tariffs on imported branded or patented pharmaceutical products from October 1, 2025, unless companies build US manufacturing facilities. This policy primarily ...
Trump’s 100% tariffs on pharma: Sun Pharma, Biocon, Cipla & other pharmaceutical stocks tank; jitters on D-Street
Pharmaceutical stocks, particularly Indian firms, plummeted following President Trump’s announcement of 100% tariffs on imported branded medicines to the US. Companies like Sun Pharma, Biocon, ...
IPO rush in India’s pharma sector: Sector eyes Rs 12,000 crore fundraising; 15 companies ready to enter market
India’s Pharma Sector Prepares for a Funding Surge: A New Wave of IPOs The Indian pharmaceutical sector is buzzing with activity, and the energy isn’t ...
Pharma sector outlook: ICRA pegs 7-9% revenue growth for FY26, US headwinds cloud prospects
India’s pharmaceutical sector is poised for strong revenue growth, projecting 7-9% in FY26, driven by domestic and European demand. While US market growth may moderate, ...
`Indian pharma resilient to potential US tariffs’
India Ratings and Research (Ind-Ra) anticipates minimal credit profile impact on Indian pharma companies from potential US tariffs on pharmaceutical imports. While the US accounts ...
Zydus Lifesciences Q1 net profit rises 3% to Rs 1,467 crore
Zydus Lifesciences: Steady Growth & a Future Focused on Innovation The pharmaceutical landscape is a constantly evolving arena, a complex dance between scientific breakthroughs, regulatory ...
